Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
出版年份 2019 全文链接
标题
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
作者
关键词
Neuroendocrine tumours, Peptide receptor radionuclide therapy, <sup>177</sup>Lu-octreotate, <sup>177</sup>Lu-DOTATATE, Somatostatin receptor, Radiosensitization, Receptor upregulation, Tumour perfusion, DNA damage
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-06
DOI
10.1007/s00259-019-04499-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Dosimetric analysis of patients with gastro-entero-pancreatic neuro endocrine tumors (NETs) treated with PRCRT (Peptide Receptor Chemo Radionuclide Therapy) using Lu-177 DOTATATE and Capecitabine/Temozolamide (CAP/TEM)
- (2018) Parul Thakral et al. BRITISH JOURNAL OF RADIOLOGY
- PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
- (2018) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
- (2018) Jonathan Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
- (2018) Martin H. Cherk et al. CANCER IMAGING
- Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
- (2018) Nupur K. Purohit et al. Oncotarget
- Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
- (2018) Michela Del Prete et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- TARGETED ALPHA PARTICLE THERAPY FOR NEUROENDOCRINE TUMOURS: THE NEXT GENERATION OF PRRT
- (2018) Ashley Grossman et al. NEUROENDOCRINOLOGY
- NAD Metabolism in Cancer Therapeutics
- (2018) Keisuke Yaku et al. Frontiers in Oncology
- Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
- (2017) Anna Sundlöv et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
- (2017) Rebecca Gupte et al. GENES & DEVELOPMENT
- Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- (2017) Hendrik Bergsma et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor Antagonists for Imaging and Therapy
- (2017) Melpomeni Fani et al. JOURNAL OF NUCLEAR MEDICINE
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
- (2017) Johanna Dalmo et al. EJNMMI Research
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Peptide receptor radionuclide therapy of neuroendocrine tumours
- (2016) Tessa Brabander et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
- (2016) Angela Lamarca et al. CANCER TREATMENT REVIEWS
- Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study
- (2016) C.M.L. Driessen et al. EUROPEAN JOURNAL OF CANCER
- Upregulation of Key Molecules for Targeted Imaging and Therapy
- (2016) V. F. Taelman et al. JOURNAL OF NUCLEAR MEDICINE
- Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours
- (2016) Katarzyna Stępień et al. MEDICAL ONCOLOGY
- Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine–temozolamide
- (2016) Sandip Basu et al. NUCLEAR MEDICINE COMMUNICATIONS
- Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
- (2016) Matthew H. Wong et al. PLoS One
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- Combining radiotherapy with sunitinib: lessons (to be) learned
- (2015) Esther A. Kleibeuker et al. ANGIOGENESIS
- NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
- (2015) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Towards tailored radiopeptide therapy
- (2015) Piotr Radojewski et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
- (2015) Seong-Jang Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide–drug conjugate via activating somatostatin receptor type II
- (2015) Lichun Sun et al. JOURNAL OF DRUG TARGETING
- Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
- (2015) E. Ilan et al. JOURNAL OF NUCLEAR MEDICINE
- Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells
- (2015) Yvonne Arvidsson et al. NEUROENDOCRINOLOGY
- Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy
- (2015) Phillip G. Claringbold et al. NEUROENDOCRINOLOGY
- Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells
- (2015) Mustafa Degirmenci et al. TUMOR BIOLOGY
- Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185
- (2015) X. Fan et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
- (2015) Sander M. Bison et al. EJNMMI Research
- Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes
- (2014) Julie Hallet et al. CANCER
- Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside
- (2014) Jeremy Lewin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
- (2014) G. Kong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
- (2014) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Angiogenesis and vascular maturation in neuroendocrine tumors
- (2014) Samaneh Yazdani et al. HUMAN PATHOLOGY
- Constitutive and follicle-stimulating hormone-induced action of somatostatin receptor-2 on regulation of apoptosis and steroidogenesis in bovine granulosa cells
- (2014) Hasan Riaz et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
- (2014) C. Kratochwil et al. MOLECULAR IMAGING AND BIOLOGY
- Hematological Toxicity of Combined177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
- (2014) Murali Kesavan et al. NEUROENDOCRINOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
- (2014) Sander M Bison et al. EJNMMI Research
- Agonist-biased Trafficking of Somatostatin Receptor 2A in Enteric Neurons
- (2013) Peishen Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer
- (2012) S. E. Pool et al. CANCER RESEARCH
- Radiation Induces Up-Regulation of Somatostatin Receptors 1, 2, and 5 in Small Cell Lung Cancer In Vitro Also at Low Absorbed Doses
- (2011) Jenny Oddstig et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- (2011) A. R. Haug et al. JOURNAL OF NUCLEAR MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice
- (2011) Jenny Oddstig et al. TUMOR BIOLOGY
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- (2010) Daniel Hubble et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway
- (2010) Karine Villaume et al. NEUROENDOCRINOLOGY
- High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
- (2009) Grace Kong et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours
- (2009) V. Zamora et al. DIGESTIVE AND LIVER DISEASE
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
- (2009) M. Watson et al. MOLECULAR AND CELLULAR BIOLOGY
- Endothelin-Converting Enzyme-1 Degrades Internalized Somatostatin-14
- (2008) Dirk Roosterman et al. ENDOCRINOLOGY
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
- (2008) Martijn van Essen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor effects of somatostatin
- (2008) Stéphane Pyronnet et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation
- (2008) Tapan K. Nayak et al. NUCLEAR MEDICINE AND BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search